UroGen Pharma (URGN) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
Estimate-vs-actual scoring began Jul 2026. Earlier quarters predate our snapshots, so their surprise stays "—". We never backfill an estimate we didn't observe.
| Report | Act EPS | Act rev | Reaction |
|---|---|---|---|
| May 6, 20268-K, before open · 8:01 am ET | −0.47b | $51.0M | +10.2%release day |
| Mar 2, 20268-K, before open · 8:08 am ET | −0.55c | $37.8M | −12.4%release day |
| Nov 6, 20258-K, before open · 8:00 am ET | −0.69b | $27.5M | +21.9%release day |
| Aug 7, 20258-K, before open · 8:01 am ET | −1.05b | $24.2M | −7.1%release day |
| May 12, 20258-K, before open · 8:03 am ET | −0.92b | $20.3M | +7.3%release day |
| Mar 10, 20258-K, before open · 8:02 am ET | −0.88c | $24.6M | +1.0%release day |
| Nov 6, 20248-K, before open · 8:01 am ET | −0.51b | $25.2M | +0.2%release day |
| Aug 13, 20248-K, before open · 8:01 am ET | −0.82b | $21.8M | +3.1%release day |
b Basic EPS. The company's diluted figure is not in our data feed for this period; its reported basic EPS agrees with net income to common shareholders over basic shares within 2%, so it is shown instead.
c Computed by Tenet. The company's diluted figure is not in our data feed for this period, so this is net income attributable to common shareholders divided by the larger of the weighted basic and diluted share counts.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 5 | 3 | 5 | 6 |
| Avg estimate | 0.39 | 0.32 | −0.37 | 2.50 |
| Low estimate | 0.02 | 0.07 | −0.79 | 0.56 |
| High estimate | 0.62 | 0.54 | −0.11 | 4.40 |
| Year-ago EPS | −0.55 | −0.47 | −3.19 | −0.37E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 5 | 3 | 5 | 5 |
| Avg estimate | $107.1M | $112.6M | $319.5M | $534.8M |
| Low estimate | $96.0M | $111.8M | $308.5M | $472.1M |
| High estimate | $115.0M | $113.3M | $327.3M | $634.8M |
| Year-ago revenue | $37.8M | $51.0M | $109.8M | $319.5ME |
| Implied growth | +183.0% | +120.9% | +191.0% | +67.4% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | 0.39 | 0.32 | −0.37 | 2.50 |
| 7 days ago | 0.43 | — | −0.27 | 2.71 |
| 30 days ago | 0.40 | — | −0.22 | 2.51 |
| 60 days ago | 0.40 | — | −0.22 | 2.51 |
| 90 days ago | 0.33 | — | −0.33 | 2.87 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $0.33 → $0.39 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
How did UroGen Pharma's stock move after its last earnings report?
UroGen Pharma moved +10.2% in the session after its May 6, 2026 report.

